For Major Health Industry Players, Reform’s Positives Outweigh Negatives

When Congress and the White House began talking about a health care overhaul, the industries that profit from the $2.5 trillion system were understandably nervous.

Graphic: Pluses and Minuses


But as the legislation takes shape, it appears much of the anxiety was misplaced. Most of the major health care players, including hospitals, health insurers and pharmaceutical companies, are likely to benefit – some handsomely – over the long term.

While hospitals and drug makers have made deals with President Barack Obama and the Senate Finance Committee to help finance the overhaul, in the end their profits could soar as more people have insurance coverage.

“Everyone has been nicked a little bit, but they are all flesh wounds,” said Nancy Chockley, president of the National Institute for Health Care Management, a nonpartisan health policy research organization funded by Blue Cross and Blue Shield plans and government grants.

To be sure, lawmakers have yet to reach agreement on key issues that could have far-reaching effects on insurance companies and providers. They include proposals to set up a government-run health plan to compete with insurers and an independent commission to exert broad authority over Medicare spending.

And it isn’t clear whether the highly publicized deals — in which the industries agreed on savings to help pay for overhaul — will hold.

But for now, “it appears the goal of the health overhaul is to expand coverage and contain costs, but without imposing too much pain on any one industry sector,” said Jack Hoadley, a health policy analyst at Georgetown University.

Here’s a scorecard showing where the various industries stand:

HOSPITALS

Worried they would have to pay too high a price for the overhaul, the hospitals were the first industry sector to make a deal with Obama and the Senate Finance Committee. Hospital groups agreed to give up $155 billion in Medicare funds over the next decade, or about an 8 percent cut. But the industry believes it will gain $170 billion by having to treat fewer uninsured patients.

“The hospitals did quite well for themselves,” said Sheryl Skolnick, a hospital analyst with CRT Capital Group in Stamford, Conn.

But Skolnick and other experts note that health overhaul will affect individual hospitals differently. For instance, hospitals that treat greater numbers of uninsured — generally urban and public hospitals — will gain the most, while those most dependent on Medicare may face the biggest financial risks because of proposed cuts.

Pluses:

Minuses: 

Mixed: 

HEALTH INSURERS


Health insurers have become the most vilified industry in the reform debate lately. That’s partly because their profits and cost-control strategies make them an easy target, and partly because Democrats are nervous that support for the health overhaul is slipping in the polls and want to remind Americans about problems with the current health system.

Last spring, the insurance industry offered its own deal to policymakers: If the government would require all Americans to have insurance coverage, the insurers would agree to accept all applicants and not charge higher premiums because of a person’s medical history.

But the industry has staunchly opposed a government-run public plan, saying it would lead to a government takeover of the health insurance field.

“The insurance industry won’t be big gainers from reform if they are the whipping boy for all that is wrong in health care,” Chockley said.

Pluses: 

Minuses:

Mixed:

PHARMACEUTICAL COMPANIES

In a deal with the White House and the Senate Finance Committee, the drug industry has agreed to put up about $80 billion to help finance the expansion of health coverage. But the industry is likely to make that up by having more Americans insured so they can buy brand-name drugs.

In the deal, the drug industry pledged to sell brand-name drugs for half price to senior citizens when they hit the gap or “doughnut hole” in their Medicare Part D benefit. In the coverage gap, seniors have to pay the full cost of drugs on their own. The discount would start soon after the health overhaul bill is approved.

Another part of the $80 billion deal includes drugmakers paying higher rebates for medicines sold to individuals eligible for both Medicaid and Medicare. Drug industry rebates were reduced when the Medicare prescription drug benefit was established in 2003, but the overhaul bill would restore some.

In the deal, the pharmaceutical industry has won concessions from the White House that drug reimportation laws would not be changed to make it easier for Americans to buy less expensive drugs from abroad.

But it did not win any promises that would preclude congressional attempts to allow the government to negotiate lower drug prices under Medicare.

“If the price negotiation goes away, I think there is a real good chance the drug industry stands to gain from health reform,” said Frank Palumbo, director of the Center on Drugs and Public Policy at the University of Maryland. 

Pluses:

Minuses:

DOCTORS

Pluses:

Minuses:

Mixed:

NURSING HOMES

Because most nursing home patients are covered by Medicare or Medicaid, reducing the number of uninsured doesn’t really help the facilities. As a result, the industry doesn’t see much gain in the overhaul.

Pluses:

Minuses:

Exit mobile version